CN110003224B - Pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof - Google Patents

Pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof Download PDF

Info

Publication number
CN110003224B
CN110003224B CN201910364487.4A CN201910364487A CN110003224B CN 110003224 B CN110003224 B CN 110003224B CN 201910364487 A CN201910364487 A CN 201910364487A CN 110003224 B CN110003224 B CN 110003224B
Authority
CN
China
Prior art keywords
methylphenyl
terpinene cycloaddition
substituted maleimide
alpha
terpinene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910364487.4A
Other languages
Chinese (zh)
Other versions
CN110003224A (en
Inventor
王玮
邓莉平
杜轶君
杨群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heilongjiang Kanglai Biomedical Technology Co ltd
Original Assignee
Shaoxing University Yuanpei College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaoxing University Yuanpei College filed Critical Shaoxing University Yuanpei College
Priority to CN201910364487.4A priority Critical patent/CN110003224B/en
Publication of CN110003224A publication Critical patent/CN110003224A/en
Application granted granted Critical
Publication of CN110003224B publication Critical patent/CN110003224B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative and a preparation method and application thereof, 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride and p-methylaniline are respectively dissolved in an acetone solvent, p-methylaniline solution is dripped into a reaction bottle containing 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride solution under stirring to prepare an N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition product, then the N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition product and 6-fluoro chromone phenylhydrazone are mixed in absolute ethanol, the N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative containing the pyrazole structure, which is prepared by adding chloramine T, has stronger inhibitory activity on HL-60 and Bel-7402, and provides a foundation for the development and research of potential drugs.

Description

Pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative containing a pyrazole structure, and a preparation method and application thereof.
Background
The chemical structural formula of the N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative is shown in figure 1. The 1, 3-dipolar cycloaddition reaction is the most important method for synthesizing five-membered heterocyclic compounds with good regioselectivity and body selectivity, and is also a more active reaction in heterocyclic pharmaceutical chemistry research.
In recent years, chromones have received much attention due to a wide range of biological activities, such as anticancer, antibacterial, inhibition of platelet aggregation, and the like. Therefore, the heterocyclic compound has high synthetic value in terms of pharmacology and synthesis angle. Pyrazole derivatives have attracted considerable attention as a class of useful intermediates and as a variety of pharmaceutical activities that they themselves exhibit.
The influence of different heterocycles on the pharmacological activity caused by the aggregation of the same molecule is researched, the pyrazole N-p-methylphenyl maleimide alpha-terpinene cycloaddition derivative containing the chromone structure is synthesized through the dipolar cycloaddition reaction, and the method has important significance in the field of medicine research.
Disclosure of Invention
The invention aims to provide an N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative containing a pyrazole structure, and a preparation method and application thereof.
In order to achieve the purpose, the technical scheme of the invention is as follows:
the N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative containing a pyrazole structure has the following chemical structural formula:
Figure GDA0002850018290000021
the invention relates to a preparation method of a pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative, which is characterized in that the preparation method of the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative comprises the following steps:
respectively dissolving 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride and p-methylaniline in an acetone solvent, adding p-methylaniline solution dropwise into a reaction bottle containing 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride solution under stirring, discharging heat in the reaction, gradually generating light yellow precipitate, reacting at room temperature for 1-2 hours, adding manganese acetate, triethylamine and acetic anhydride into the reaction bottle in sequence, reacting, heating, gradually dissolving the precipitate, reacting for 5-8 hours at 50-60 ℃, changing the solution from orange yellow to red black, cooling to room temperature, washing and drying the precipitate in a large amount of water, and recrystallizing with acetone to obtain a product N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition product;
mixing the N-p-methylphenyl maleimide alpha-terpinene cycloaddition product and 6-fluorochromone phenylhydrazone in absolute ethyl alcohol, adding chloramine T, refluxing for 12-15 hours, carrying out addition reaction, recrystallizing with methanol, and drying in vacuum to obtain the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative.
Further, the dissolving of 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) and p-methylaniline (compound 2) in an acetone solvent, respectively, comprises:
adding 2mmol of 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride into 20-30 mL of acetone solvent;
adding 2mmol of p-methylaniline into 20-30 mL of acetone solvent.
Further, the molar ratio of the N-p-methylphenyl maleimide α -terpinene cycloaddition product, 6-fluorochromone phenylhydrazone, and chloramine T is 1: 1: 1-1.5.
Further, the sequentially adding manganese acetate, triethylamine and acetic anhydride comprises:
adding 0.3-0.5 g of manganese acetate into 40-60 mL of acetone solvent;
adding 15-20mL of triethylamine into 40-60 mL of acetone solvent;
30-35mL of acetic anhydride is added into 40-60 mL of acetone solvent.
Further, the N-p-methylphenyl maleimide alpha-terpinene cycloaddition product and 6-fluoro chromone phenylhydrazone are mixed in anhydrous ethanol, wherein 1mmol of the N-p-methylphenyl maleimide alpha-terpinene cycloaddition product and 1mmol of the 6-fluoro chromone phenylhydrazone are added in every 20-25mL of the anhydrous ethanol.
The invention also provides application of the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative in preparation of antitumor drugs.
The invention provides an N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative containing a pyrazole structure, a preparation method and application thereof, wherein the pharmacological activity can be changed by introducing a chromone structure on the basis of introducing a five-membered pyrazole ring structure into an N-p-methylphenyl maleimide alpha-terpinene cycloaddition product, 6-fluoro chromone phenylhydrazone substituted by formaldehyde group at the 3-position is used for substituting on the structure of pyrazole, the N-p-methylphenyl maleimide alpha-terpinene cycloaddition product is structurally modified, and the prepared N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative containing the pyrazole structure has stronger inhibitory activity on HL-60 (leukemia cells) and Bel-7402 (human liver cancer cells), provides a foundation for the development and research of the compound for potential drugs.
Drawings
FIG. 1 is a chemical structural formula of a cycloaddition derivative of N-p-methylphenyl substituted maleimide alpha-terpinene;
FIG. 2 is a chemical structural formula of the pyrazole-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative;
FIG. 3 is a chemical formula diagram of a preparation method of the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative.
Detailed Description
The technical solutions of the present invention are further described in detail below with reference to the drawings and examples, which should not be construed as limiting the present invention.
Researches show that the pharmacological activity can be changed by introducing the structure of chromone on the basis of introducing a five-membered pyrazole ring structure into an N-p-methylphenyl maleimide alpha-terpinene cycloaddition product. The experimental data are as follows:
Figure GDA0002850018290000041
TABLE 1
Based on the above experimental data, the structural modification of the N-p-methylphenyl maleimide alpha-terpinene cycloaddition product was carried out using 6-fluorochromone phenylhydrazone substituted with formaldehyde group at the 3-position in the present application for substitution on the structure of pyrazole.
The chemical structural formula of the N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative containing a pyrazole structure is shown in figure 2.
In one embodiment, a method for preparing an N-p-methylphenyl substituted maleimide α -terpinene cycloaddition derivative having a pyrazole structure comprises:
respectively dissolving 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) and p-methylaniline (compound 2) in an acetone solvent, dropwise adding the p-methylaniline solution (compound 2) into a reaction bottle containing the 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) solution under stirring, discharging heat and gradually generating light yellow precipitates, reacting at room temperature for 1-2 hours, sequentially adding manganese acetate, triethylamine and acetic anhydride into the reaction bottle, reacting for 1-2 hours, heating, gradually dissolving the precipitates, reacting at 50-60 ℃ for 5-8 hours, changing the solution from orange yellow to red black, cooling to room temperature, washing the precipitate with a large amount of water, drying, and recrystallizing with acetone to obtain N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition product (compound 3);
mixing the N-p-methylphenyl maleimide alpha-terpinene cycloaddition product (compound 3) and 6-fluorochromone phenylhydrazone (compound 4) in absolute ethyl alcohol, adding chloramine T, refluxing for 12-15 hours, carrying out addition reaction, recrystallizing with methanol, and drying in vacuum to obtain the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative (compound 5).
Wherein the chemistry of compound 3 is collectively referred to as: 1-isopropyl-4-methyl-bicyclo [2,2,2] -5-octene-2, 3- (N-p-methylphenyl) dicarboximide, abbreviated in this example as N-p-methylphenyl substituted maleimide α -terpinene cycloaddition product.
While the chemistry of compound 5 is collectively referred to as: 3- (6-fluoro-chromon-3-yl) -1-phenyl-7-methyl-4-isopropyl-bicyclo [2,2,2] octa [2,3-d ]3aH,7aH pyrazole-2, 3- (N-p-methylphenyl) dicarboximide, referred to in this example as the pyrazole-containing N-p-methylphenyl substituted maleimide α -terpinene cycloaddition derivative.
Wherein, the synthesis of the 6-fluorochromone phenylhydrazone (compound 4) can be synthesized by a method of generating Schiff base by dehydration reaction of 6-fluorochromone with substituted formaldehyde group at the 3 position and phenylhydrazine.
Example 1, 2mmol phenylhydrazine was added to a flask containing 10mL tetrahydrofuran, and the mixture was stirred under reflux in a boiling water bath until dissolved, then 20mL absolute ethanol solution in which 2mmol of 6-fluorochromone substituted with a formaldehyde group at the 3-position was dissolved was slowly added dropwise, and the mixture was stirred under reflux in a boiling water bath for 1 hour, and 10 drops of hydrochloric acid were added dropwise, and a pale yellow precipitate appeared. And (3) refluxing and stirring in a continuous boiling water bath for 5 hours, stopping the water bath, adding 20mL of distilled water, stirring, deepening the color of a light yellow precipitate, and performing suction filtration to obtain a yellow-red needle-shaped product of 6-fluorochromone phenylhydrazone. Washing with anhydrous ether for several times, and vacuum drying to obtain the product 6-fluorochromone phenylhydrazone (compound 4).
The present invention is not limited to the method for synthesizing 6-fluorochromone phenylhydrazone (compound 4), and the chemical name of compound 4 may be expressed as: 6-fluoro-chromone-3-phenylhydrazone, which is not described in detail herein.
In one example, 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) and p-methylaniline (compound 2) were dissolved in acetone solvents, respectively, comprising:
adding 2mmol of 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride into 20-30 mL of acetone solvent;
adding 2mmol of p-methylaniline into 20-30 mL of acetone solvent.
In one embodiment, the molar ratio of N-p-methylphenylmaleimide α -terpinene cycloaddition product, 6-fluorochromone phenylhydrazone, and chloramine T is 1: 1: 1-1.5.
In one embodiment, manganese acetate, triethylamine and acetic anhydride are added sequentially, including:
adding 0.3-0.5 g of manganese acetate into 40-60 mL of acetone solvent;
adding 15-20mL of triethylamine into 40-60 mL of acetone solvent;
30-35mL of acetic anhydride is added into 40-60 mL of acetone solvent.
In one example, the N-p-methylphenylmaleimide α -terpinene cycloaddition product and 6-fluorochromone phenylhydrazone are mixed in anhydrous ethanol, wherein 1mmol of the N-p-methylphenylmaleimide α -terpinene cycloaddition product and 1mmol of the 6-fluorochromone phenylhydrazone are added per 20-25mL of the anhydrous ethanol.
The preparation of the N-p-methylphenyl substituted maleimide α -terpinene cycloaddition derivative (compound 5) containing the pyrazole structure of the present application is illustrated in detail by the following specific examples:
examples 2,
1) And synthesis of N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition product: respectively dissolving 2mmol of 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) and 2mmol of p-methylaniline (compound 2) in 20mL of acetone solvent, dropwise adding the p-methylaniline solution into a reaction bottle containing the 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) solution under stirring, reacting for 1 hour at room temperature, sequentially adding 0.3 g of manganese acetate, 15mL of triethylamine and 30mL of acetic anhydride into the reaction bottle, reacting for 1 hour at room temperature, heating, gradually dissolving the precipitate, reacting for 5 hours at 50-60 ℃, changing the solution from orange yellow to red black, cooling to room temperature, the precipitate was washed with a large amount of water, dried, and recrystallized from acetone to give the product N-p-methylphenyl-substituted maleimide α -terpinene cycloaddition product (Compound 3).
2) Introduction of a pyrazole structure: mixing 1mmol of N-p-methylphenyl maleimide alpha-terpinene cycloaddition product (compound 3) and 1mmol of 6-fluorochromone phenylhydrazone (compound 4) in 20mL of absolute ethyl alcohol, adding 1.2mmol of chloramine T, refluxing for 12 hours, performing addition reaction, recrystallizing with methanol, and drying in vacuum to obtain the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative (compound 5).
Examples 3,
1) And synthesis of N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition product: respectively dissolving 2mmol of 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) and 2mmol of p-methylaniline (compound 2) in 30mL of acetone solvent, dropwise adding the p-methylaniline solution into a reaction bottle containing the 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) solution under stirring, reacting for 2 hours at room temperature while releasing heat and gradually generating light yellow precipitates, sequentially adding 0.5 g of manganese acetate, 20mL of triethylamine and 35mL of acetic anhydride into the reaction bottle, reacting for 2 hours at room temperature while heating, gradually dissolving the precipitates, reacting for 8 hours at 50-60 ℃, changing the solution from orange yellow to red black, cooling to room temperature, the precipitate was washed with a large amount of water, dried, and recrystallized from acetone to give the product N-p-methylphenyl-substituted maleimide α -terpinene cycloaddition product (Compound 3).
2) Introduction of a pyrazole structure: mixing 1mmol of N-p-methylphenyl maleimide alpha-terpinene cycloaddition product (compound 3) and 1mmol of 6-fluorochromone phenylhydrazone (compound 4) in 25mL of absolute ethyl alcohol, adding 1.5mmol of chloramine T, refluxing for 15 hours, carrying out addition reaction, recrystallizing with methanol, and carrying out vacuum drying to obtain the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative (compound 5).
Examples 4,
1) And synthesis of N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition product: respectively dissolving 2mmol of 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) and 2mmol of p-methylaniline (compound 2) in 25mL of acetone solvent, dropwise adding the p-methylaniline solution into a reaction bottle containing the 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride (compound 1) solution under stirring, reacting for 2 hours at room temperature while releasing heat and gradually generating light yellow precipitates, sequentially adding 0.4 g of manganese acetate, 18mL of triethylamine and 33mL of acetic anhydride into the reaction bottle, reacting for 2 hours at room temperature while heating, gradually dissolving the precipitates, reacting for 6 hours at 50-60 ℃, changing the solution from orange yellow to red black, cooling to room temperature, the precipitate was washed with a large amount of water, dried, and recrystallized from acetone to give the product N-p-methylphenyl-substituted maleimide α -terpinene cycloaddition product (Compound 3).
2) Introduction of a pyrazole structure: mixing 1mmol of N-p-methylphenyl maleimide alpha-terpinene cycloaddition product (compound 3) and 1mmol of 6-fluorochromone phenylhydrazone (compound 4) in 25mL of absolute ethyl alcohol, adding 1.4mmol of chloramine T, refluxing for 13 hours, performing addition reaction, recrystallizing with methanol, and drying in vacuum to obtain the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative (compound 5).
Figure 3 shows the preparation of compound 5 of the present application, wherein 1 represents compound 1, 2 represents compound 2,3 represents compound 3, 4 represents compound 4, and 5 represents compound 5.
The experimental data are as follows:
the N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative (compound 5) containing pyrazole structure is light yellow crystal, the yield is 46.5 percent, and the m.p.164-165 ℃.
1H NMR(DMSO)δ:7.28-7.49(m,12H,Ar-H),6.47(s,1H,C＝C-H),6.01(d,J＝8.5Hz,1H,H-5),6.09(1H,d,J＝8.5Hz,1H,H-6),2.34(s,3H,CH3),3.13(1H,d,J＝8.9Hz,1H H-2),2.85(1H,d,J＝8.9Hz,1H,H-3),1.34(1H,m,H-7a),1.47(1H,m,H-7b),1.33(1H,m,H-8a),1.47(1H,m,H-8b),2.56(1H,m,H-9),1.01(3H,d,J＝7.0Hz,H-10),1.07(3H,d,J＝6.7Hz,H-11),1.50(3H,s,H-12).
IR 3457(N-C＝O),3085(ArH),1726(C＝O),1575(C＝N),1298(C-O-C)cm-1
m/e:603(100.0％)。
Anal.calcd.for C37H34FN3O4：C,73.61；H,5.68；N,6.96。
The result of measuring the antitumor activity of the pyrazole-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative (compound 5) is as follows:
MTT assay compound 5 was tested for in vitro inhibition of different tumor strains:
compound 5 was dissolved and diluted in DMSO, and tumor cells Bel-7402 (human liver cancer cells), KB (oral cancer cells), SGC7901 (gastric cancer cells), HO8901 (ovarian cancer cells), HL-60 (leukemia cells), ECA109 (intestinal cancer cells) were seeded in 4000/200. mu.L/well in 96-well plates, 2. mu.L of compound was added to each well to a final concentration of 12.0. mu.M, 6.0. mu.M, 3.0. mu.M, 1.5. mu.M, and incubated in a 37 ℃ 5% CO2 cell incubator for 72 hours with DMSO (1%) as a blank. After 72 hours, MTT was added to a final concentration of 0.25mg/mL, the mixture was placed in a 5% CO2 cell incubator at 37 ℃ for 4 hours, the solvent was then blotted, 100. mu.l DMSO was added to each well, and the absorbance (OD value) was measured at 570nm using an enzyme-linked immunosorbent assay, and the data obtained was used to calculate the IC50 value. Selecting compounds with high inhibitory activity, and determining the influence of different action times of the compounds at different concentrations on the human tumor cell cycle and apoptosis.
The test compounds at various concentrations were coarse-screened in 96-well plates and, based on the resulting inhibition, IC50 values were calculated and the results are shown in the following table:
Figure GDA0002850018290000091
TABLE 2
Table 2 shows the IC of N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative (compound 5) containing pyrazole structure on six tumor cell lines50The value and the result show that the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative (compound 5) has stronger inhibitory activity on HL-60 (leukemia cells) and Bel-7402 (human liver cancer cells), and provides a foundation for the development and research of potential medicaments.
The above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and those skilled in the art can make various corresponding changes and modifications according to the present invention without departing from the spirit and the essence of the present invention, but these corresponding changes and modifications should fall within the protection scope of the appended claims.

Claims (7)

1. The pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative is characterized in that the chemical structural formula of the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative is as follows:
Figure FDA0002850018280000011
2. the process for preparing the pyrazole structure-containing N-p-methylphenyl-substituted maleimide α -terpinene cycloaddition derivative according to claim 1, wherein the process for preparing the pyrazole structure-containing N-p-methylphenyl-substituted maleimide α -terpinene cycloaddition derivative comprises:
respectively dissolving 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride and p-methylaniline in an acetone solvent, adding p-methylaniline solution dropwise into a reaction bottle containing 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride solution under stirring, discharging heat in the reaction, gradually generating light yellow precipitate, reacting at room temperature for 1-2 hours, adding manganese acetate, triethylamine and acetic anhydride into the reaction bottle in sequence, reacting, heating, gradually dissolving the precipitate, reacting for 5-8 hours at 50-60 ℃, changing the solution from orange yellow to red black, cooling to room temperature, washing and drying the precipitate in a large amount of water, and recrystallizing with acetone to obtain a product N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition product;
mixing the N-p-methylphenyl maleimide alpha-terpinene cycloaddition product and 6-fluorochromone phenylhydrazone in absolute ethyl alcohol, adding chloramine T, refluxing for 12-15 hours, carrying out addition reaction, recrystallizing with methanol, and drying in vacuum to obtain an N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative containing a pyrazole structure;
wherein the chemical structural formula of the N-p-methylphenyl maleimide alpha-terpinene cycloaddition product is as follows:
Figure FDA0002850018280000021
the chemical structural formula of the 6-fluorochromone phenylhydrazone is as follows:
Figure FDA0002850018280000022
3. the method for preparing the pyrazole structure-containing N-p-methylphenyl substituted maleimide α -terpinene cycloaddition derivative according to claim 2, wherein the dissolving of 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride and p-methylaniline in an acetone solvent respectively comprises:
adding 2mmol of 1-isopropyl-4-methyl-bicyclo [2,2,2] oct-5-ene-2, 3-dicarboxylic anhydride into 20-30 mL of acetone solvent;
adding 2mmol of p-methylaniline into 20-30 mL of acetone solvent.
4. The method for preparing the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative according to claim 2, wherein the molar ratio of the N-p-methylphenyl maleimide alpha-terpinene cycloaddition product, 6-fluorochromone phenylhydrazone and chloramine T is 1: 1: 1-1.5.
5. The method for preparing the pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative according to claim 2, wherein the sequentially adding manganese acetate, triethylamine and acetic anhydride comprises:
adding 0.3-0.5 g of manganese acetate into 40-60 mL of acetone solvent;
adding 15-20mL of triethylamine into 40-60 mL of acetone solvent;
30-35mL of acetic anhydride is added into 40-60 mL of acetone solvent.
6. The method for preparing the N-p-methylphenyl substituted maleimide α -terpinene cycloaddition derivative according to claim 2, wherein the N-p-methylphenyl maleimide α -terpinene cycloaddition derivative and the 6-fluorochromone phenylhydrazone are mixed in anhydrous ethanol, wherein 1mmol of the N-p-methylphenyl maleimide α -terpinene cycloaddition derivative and 1mmol of the 6-fluorochromone phenylhydrazone are added to 20-25mL of the anhydrous ethanol.
7. The use of the pyrazole structure-containing N-p-methylphenyl substituted maleimide α -terpinene cycloaddition derivative according to claim 1 in the preparation of an antitumor medicament.
CN201910364487.4A 2019-04-30 2019-04-30 Pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof Active CN110003224B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910364487.4A CN110003224B (en) 2019-04-30 2019-04-30 Pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910364487.4A CN110003224B (en) 2019-04-30 2019-04-30 Pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN110003224A CN110003224A (en) 2019-07-12
CN110003224B true CN110003224B (en) 2021-08-24

Family

ID=67175444

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910364487.4A Active CN110003224B (en) 2019-04-30 2019-04-30 Pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN110003224B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR392301A0 (en) * 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
CN103896954B (en) * 2013-11-15 2016-02-17 绍兴文理学院 A kind of pyrazoles norcantharidin derivative and preparation method thereof and application
CN106397445B (en) * 2016-04-29 2018-05-29 绍兴文理学院 Pyrazoles N- p-bromophenyl maleimide derivatives containing chromone structure and preparation method and application

Also Published As

Publication number Publication date
CN110003224A (en) 2019-07-12

Similar Documents

Publication Publication Date Title
CN109053731B (en) P-chloro-substituted pyridazinone-structure-containing spiro [ indolizine-pyrazoline ] derivative and preparation method and application thereof
CN110003224B (en) Pyrazole structure-containing N-p-methylphenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof
CN110105364B (en) Pyrazole structure-containing N-p-chlorophenyl substituted maleimide alpha-terpinene cycloaddition derivative, and preparation method and application thereof
CN109988177B (en) Pyrazole structure-containing N-p-methoxyphenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof
CN109988176B (en) Pyrazole structure-containing N-p-bromophenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof
CN109988178B (en) Pyrazole structure-containing N-p-nitrophenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof
CN110128444B (en) P-nitrophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof
CN109988179B (en) Pyrazole structure-containing N-phenyl substituted maleimide alpha-terpinene cycloaddition derivative and preparation method and application thereof
CN101863766B (en) Beta-hydroxyisovalerylshikonin derivative and preparation method thereof
CN111303027A (en) Fluroxacin acrylketone derivative and preparation method and application thereof
CN111269228A (en) Preparation method of indolizine ring-1, 2-diketone and derivative thereof with fluorescence activity
CN107698571B (en) Naphthalimide-coumarin DNA targeting double-intercalator, synthesis and application thereof
CN108947916B (en) Perimidine quinone derivative and preparation method and application thereof
CN109180583B (en) Synthesis and application of naphthalimide derivative containing heterocyclic sulfone group and N-oxide
CN110804039B (en) Phthalimide-containing 1, 8-naphthalic anhydride derivatives, pharmaceutically acceptable salts thereof and application of anti-tumor drugs thereof
CN110183467B (en) P-methoxyphenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof
CN116199687B (en) Beta-carboline-3-position connected 1,2, 3-triazole compound as well as preparation method and application thereof
CN106220642A (en) A kind of L leucine ring substituent norcantharidin derivative and preparation method and application
CN106083649B (en) A kind of synthetic method of the Cyclohexadiene derivatives of 3,5 diaryl, 2,6,6 tricyano, 1 imino group 2,4
CN110759920A (en) P-methoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof
CN114920684B (en) Selenium-containing benzamide compound and synthetic method and application thereof
CN109180675B (en) P-methoxy substituted pyridazinone structure-containing spiro [ indolizine-pyrazoline ] derivative and preparation method and application thereof
CN110734442B (en) 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure, and preparation method and application thereof
CN109180676B (en) 3,4, 5-trimethoxy substituted pyridazinone structure-containing spiro [ indolizine-pyrazoline ] derivative and preparation method thereof
CN109232572B (en) P-methyl-substituted pyridazinone-structure-containing spiro [ indolizine-pyrazoline ] derivative and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220711

Address after: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province

Patentee after: Jinan Weiyang Technology Co.,Ltd.

Address before: No. 2799, Qunxian Middle Road, Shaoxing City, Zhejiang Province

Patentee before: SHAOXING UNIVERSITY YUANPEI College

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221021

Address after: Commercial Service No. 10, Building 6, Anqing Ecological Town, Wolitun Town, Anda City, Suihua City, Heilongjiang Province 152000

Patentee after: Heilongjiang Kanglai Biomedical Technology Co.,Ltd.

Address before: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province

Patentee before: Jinan Weiyang Technology Co.,Ltd.

TR01 Transfer of patent right